Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, cilt.27, sa.1, ss.40-45, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 1
- Basım Tarihi: 2021
- Doi Numarası: 10.1177/1078155220909426
- Dergi Adı: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sayfa Sayıları: ss.40-45
- Anahtar Kelimeler: late adjuvant therapy, melanoma, survival, Temozolomide
- İstanbul Üniversitesi Adresli: Evet